{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:39:40Z","timestamp":1792521580500,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corp","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jchf.2021.01.007","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T18:39:54Z","timestamp":1617043194000},"page":"301-313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Everolimus for the Prevention of Calcineurin-Inhibitor-Induced Left Ventricular Hypertrophy After Heart Transplantation (RADTAC Study)"],"prefix":"10.1016","volume":"9","author":[{"given":"Chris","family":"Anthony","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Imran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Pouliopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Emmanuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Iliff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten J.","family":"Moffat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Kotlyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavitha","family":"Muthiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Keogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Hayward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2021.01.007_bib1","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1161\/01.CIR.0000150332.42276.69","article-title":"Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs","volume":"110","author":"Lindenfeld","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2021.01.007_bib2","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.healun.2012.08.002","article-title":"The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report--2012","volume":"31","author":"Stehlik","year":"2012","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.jchf.2021.01.007_bib3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.healun.2006.11.003","article-title":"Severe left ventricular hypertrophy 1 year after transplant predicts mortality in cardiac transplant recipients","volume":"26","author":"Goodroe","year":"2007","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.jchf.2021.01.007_bib4","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1097\/TP.0b013e318189049a","article-title":"Sirolimus as primary immunosuppressant reduces left ventricular mass and improves diastolic function of the cardiac allograft","volume":"86","author":"Raichlin","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.jchf.2021.01.007_bib5","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1432-2277.1997.tb00722.x","article-title":"Donor left ventricular hypertrophy increases risk for early graft failure","volume":"10","author":"Aziz","year":"1997","journal-title":"Transpl Int"},{"key":"10.1016\/j.jchf.2021.01.007_bib6","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/j.healun.2005.02.011","article-title":"Effects of conversion from cyclosporine to tacrolimus on left ventricular structure in cardiac allograft recipients","volume":"24","author":"Peura","year":"2005","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.jchf.2021.01.007_bib7","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.jacc.2008.06.049","article-title":"Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping","volume":"52","author":"Iles","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2021.01.007_bib8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev.physiol.65.092101.142243","article-title":"Cardiac hypertrophy: the good, the bad, and the ugly","volume":"65","author":"Frey","year":"2003","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.jchf.2021.01.007_bib9","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1093\/eurheartj\/ehn407","article-title":"Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients","volume":"29","author":"Kushwaha","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2021.01.007_bib10","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1161\/CIRCRESAHA.117.311147","article-title":"New insights into the role of mTOR signaling in the cardiovascular system","volume":"122","author":"Sciarretta","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.jchf.2021.01.007_bib11","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/ajt.13588","article-title":"Everolimus initiation with early calcineurin inhibitor withdrawal in de novo heart transplant recipients: three-year results from the randomized SCHEDULE Study","volume":"16","author":"Andreassen","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jchf.2021.01.007_bib12","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1111\/ajt.12809","article-title":"Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial","volume":"14","author":"Andreassen","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jchf.2021.01.007_bib13","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/ajt.12181","article-title":"Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial","volume":"13","author":"Eisen","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jchf.2021.01.007_bib14","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa022171","article-title":"Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients","volume":"349","author":"Eisen","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2021.01.007_bib15","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.athoracsur.2013.09.031","article-title":"Prospective study of everolimus with calcineurin inhibitor-free immunosuppression after heart transplantation: results at four years","volume":"97","author":"Engelen","year":"2014","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jchf.2021.01.007_bib16","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/01.TP.0000184006.43152.8D","article-title":"Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo\u00a0malignancies","volume":"80","author":"Kauffman","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.jchf.2021.01.007_bib17","first-page":"389","article-title":"Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial","volume":"1","author":"Kobashigawa","year":"2013","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2021.01.007_bib18","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1097\/01.hjh.0000239304.01496.83","article-title":"Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis","volume":"24","author":"Gao","year":"2006","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.jchf.2021.01.007_bib19","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1161\/01.CIR.0000130641.08705.45","article-title":"Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload","volume":"109","author":"McMullen","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2021.01.007_bib20","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/TP.0b013e318242be28","article-title":"Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients: a 1 year, randomized, controlled trial","volume":"93","author":"Paoletti","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.jchf.2021.01.007_bib21","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/ki.2008.690","article-title":"Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure","volume":"75","author":"Siedlecki","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.jchf.2021.01.007_bib22","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.healun.2005.03.019","article-title":"Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection","volume":"24","author":"Stewart","year":"2005","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.jchf.2021.01.007_bib23","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.jacc.2013.05.078","article-title":"Evaluation of age-related interstitial myocardial fibrosis with cardiac magnetic resonance contrast-enhanced T1 mapping: MESA (multi-ethnic study of atherosclerosis)","volume":"2013","author":"Liu","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2021.01.007_bib24","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1136\/heartjnl-2012-303052","article-title":"Human non-contrast T1 values and correlation with histology in diffuse fibrosis","volume":"99","author":"Bull","year":"2013","journal-title":"Heart"},{"key":"10.1016\/j.jchf.2021.01.007_bib25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12968-014-0069-x","article-title":"Reference values for healthy human myocardium using a T1 mapping methodology: results from the International T1 Multicenter cardiovascular magnetic resonance study","volume":"16","author":"Dabir","year":"2014","journal-title":"J\u00a0Cardiovasc Magn Reson"},{"key":"10.1016\/j.jchf.2021.01.007_bib26","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1161\/CIRCIMAGING.112.000151","article-title":"Native myocardial T1 mapping by cardiovascular magnetic resonance imaging in subclinical cardiomyopathy in patients with systemic lupus erythematosus","volume":"6","author":"Puntmann","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jchf.2021.01.007_bib27","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jcmg.2012.08.019","article-title":"Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy","volume":"6","author":"Puntmann","year":"2013","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jchf.2021.01.007_bib28","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.jcmg.2018.10.027","article-title":"Native T1 mapping in the diagnosis of cardiac allograft rejection: a prospective histologically validated study","volume":"12","author":"Imran","year":"2019","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jchf.2021.01.007_bib29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"\u2217Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav Res Methods"},{"key":"10.1016\/j.jchf.2021.01.007_bib30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0002-9149(02)02381-0","article-title":"Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy","volume":"90","author":"Grothues","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2021.01.007_bib31","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12968-017-0386-y","article-title":"Measurement of myocardial native T1 in cardiovascular diseases and norm in 1291 subjects","volume":"19","author":"Liu","year":"2017","journal-title":"J\u00a0Cardiovasc Magn Reson"},{"key":"10.1016\/j.jchf.2021.01.007_bib32","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jacc.2017.12.020","article-title":"Native T1 and ECV of noninfarcted myocardium and outcome in patients with coronary artery disease","volume":"71","author":"Puntmann","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2021.01.007_bib33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jcmg.2015.12.001","article-title":"T1-mapping and outcome in nonischemic cardiomyopathy: all-cause mortality and heart failure","volume":"9","author":"Puntmann","year":"2016","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jchf.2021.01.007_bib34","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.115.003285","article-title":"T1 mapping in discrimination of hypertrophic phenotypes: hypertensive heart disease and hypertrophic cardiomyopathy: findings from the International T1 Multicenter Cardiovascular Magnetic Resonance Study","volume":"8","author":"Hinojar","year":"2015","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jchf.2021.01.007_bib35","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jcmg.2020.01.014","article-title":"Prognostic value of myocardial extracellular volume fraction and T2-mapping in heart transplant patients","volume":"13","author":"Chaikriangkrai","year":"2020","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jchf.2021.01.007_bib36","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jcmg.2009.11.006","article-title":"Comparison of magnetic resonance feature tracking for strain calculation with harmonic phase imaging analysis","volume":"3","author":"Hor","year":"2010","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jchf.2021.01.007_bib37","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/ehjci\/jev227","article-title":"Direct comparison of cardiac magnetic resonance feature tracking and 2D\/3D echocardiography speckle tracking for evaluation of global left ventricular strain","volume":"17","author":"Obokata","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jchf.2021.01.007_bib38","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jcmg.2015.02.005","article-title":"The combined incremental prognostic value of LVEF, late gadolinium enhancement, and global circumferential strain assessed by CMR","volume":"8","author":"Mordi","year":"2015","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jchf.2021.01.007_bib39","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.amjcard.2019.01.025","article-title":"Usefulness of left ventricular strain by cardiac magnetic resonance feature-tracking to predict cardiovascular events in patients with and without heart failure","volume":"123","author":"Sardana","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2021.01.007_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001390","article-title":"Two-dimensional strain profiles in patients with physiological and pathological hypertrophy and preserved left ventricular systolic function: a comparative analyses","volume":"2","author":"Afonso","year":"2012","journal-title":"BMJ Open"},{"key":"10.1016\/j.jchf.2021.01.007_bib41","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1161\/01.CIR.0000150334.69355.00","article-title":"Discrimination of nonobstructive hypertrophic cardiomyopathy from hypertensive left ventricular hypertrophy on the basis of strain rate imaging by tissue Doppler\u00a0ultrasonography","volume":"110","author":"Kato","year":"2004","journal-title":"Circulation"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177921000512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177921000512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:57:26Z","timestamp":1761973046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177921000512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S2213177921000512"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2021.01.007","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Everolimus for the Prevention of Calcineurin-Inhibitor-Induced Left Ventricular Hypertrophy After Heart Transplantation (RADTAC Study)","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2021.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}